Lyka Labs Ltd
NSE: LYKALABS BSE: 500259
₹62.35
(-3.33%)
Tue, 03 Mar 2026, 11:14 pm
Market Cap2.24B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Other
24.5KLyka Labs Analysis
dividend
- Unable to evaluate Lyka Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Lyka Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Whilst loss making Lyka Labs has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -11.3% per year.
- Whilst loss making Lyka Labs has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
- Lyka Labs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Debt is not well covered by operating cash flow (3.8%, less than 20% of total debt).
- Lyka Labs has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Lyka Labs's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Lyka Labs's debt level has increased considering it has negative shareholder equity.
- Lyka Labs has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- Kunal's remuneration is about average for companies of similar size in India.
- The average tenure for the Lyka Labs board of directors is less than 3 years, this suggests a new board.
- Kunal's compensation has increased whilst company is loss making.
- The average tenure for the Lyka Labs management team is less than 2 years, this suggests a new team.
misc
- Lyka Labs is not covered by any analysts.
- Lyka Labs has significant price volatility in the past 3 months.
past
- Unable to compare Lyka Labs's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Lyka Labs does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Lyka Labs has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Lyka Labs improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Lyka Labs has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Lyka Labs's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- NSEI:LYKALABS is up 20.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:LYKALABS is up 20.2% outperforming the market in India which returned 8% over the past month.
- Lyka Labs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Lyka Labs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Lyka Labs has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Lyka Labs is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Lyka Labs is loss making, we can't compare the value of its earnings to the India market.
- LYKALABS underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- LYKALABS underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800